Publications

Found 92 results
Filters: Keyword is Humans  [Clear All Filters]
2017
Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy J-P, Havenar-Daughton C et al..  2017.  Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells.. PLoS One. 12(10):e0186998.
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD et al..  2017.  HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection.. J Virol. 91(7):e02477-16.
Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith MLaird, Eren K et al..  2017.  HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.. Immunity. 47(5):990-1003.e9.
Alsahafi N, Richard J, Prévost J, Coutu M, Brassard N, Parsons MS, Kaufmann DE, Brockman M, Finzi A.  2017.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.. J Virol. 91(16):pii:e00109-17.
Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Massanella M, Brassard N, Alsahafi N, Routy J-P, Finzi A et al..  2017.  Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique.. Nat Protoc. 12(10):2029-2049.
Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R et al..  2017.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.. Cell. 169(4):597-609.e11.
2013
Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA.  2013.  Accelerating next-generation vaccine development for global disease prevention.. Science. 340(6136):1232910.
Kulp DW, Schief WR.  2013.  Advances in structure-based vaccine design.. Curr Opin Virol. 3(3):322-31.
Crispin M, Bowden TA.  2013.  Antibodies expose multiple weaknesses in the glycan shield of HIV.. Nat Struct Mol Biol. 20(7):771-2.
Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR et al..  2013.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.. J Virol. 87(9):4985-93.
Isik G, P Y Chung N, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW.  2013.  An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells.. PLoS One. 8(6):e67309.
Porichis F, Hart MG, Zupkosky J, Barblu L, Kaufmann DE.  2013.  In vitro assay to evaluate the impact of immunoregulatory pathways on HIV-specific CD4 T cell effector function.. J Vis Exp. (80):e50821.
Klasse P J, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee J H, Marozsan AJ, Cupo A, Cocco N, Korzun J et al..  2013.  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.. J Virol. 87(17):9873-85.
Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang G-Y, M Joyce G et al..  2013.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.. Immunity. 39(2):245-58.
Sok D, Moldt B, Burton DR.  2013.  SnapShot: broadly neutralizing antibodies.. Cell. 155(3):728-728.e1.

Pages